SSSofie Seghers

Sofie Seghers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sofie Seghers has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimizing patient-derived tumor organoids for translational cancer research

    by Sofie Seghers

    Precision oncology aims to tailor cancer treatment to the biological characteristics of individual tumours. However, genomic profiling alone often fails to predict therapeutic response, highlighting the need for complementary functional approaches. Patient-derived tumour organoids (PDTOs) offer a promising platform to investigate tumour biology and therapeutic vulnerabilities. Nevertheless, their translational value depends on the reliability of their establishment, biological fidelity and experimental conditions. This thesis aimed to develop, optimize and critically evaluate a PDTO platform for translational cancer research. First, we established a multi-tumour organoid biobank at the University Hospital Antwerp and University of Antwerp, integrating standardized tissue collection, laboratory processing, quality control and clinical data management. Evaluation of 182 patient samples demonstrated substantial tumour-specific variability in establishment success, with long-term cultures obtained in 16.5% of cases. Challenges included limited tissue availability, variable growth capacity and non-malignant epithelial overgrowth, particularly in lung cancer cultures. These findings emphasize that successful biobanking requires both technical optimization and rigorous model validation. Second, we investigated the potential of PDTOs for functional drug discovery, focusing on strategies to enhance the efficacy of 5-fluorouracil (5-FU). Through iterative monotherapy, combination and pathway-focused screening, we identified inhibition of the replication-stress checkpoint, particularly the ATR–CHK1–WEE1–PKMYT1 axis, as a promising strategy to potentiate 5-FU activity. These findings illustrate the value of functional screening for identifying therapeutic vulnerabilities while emphasizing the importance of mechanistic validation. Third, we systematically investigated how culture medium influences organoid biology and pharmacological responses. Comparing conventional Wnt-based medium with OncoPro medium revealed substantial differences in transcriptional states and drug sensitivity despite preservation of major genomic alterations and tumour identity. OncoPro-grown organoids generally exhibited greater drug resistance and transcriptional profiles more closely resembling malignant epithelial states. These findings demonstrate that culture conditions are not merely technical parameters but active determinants of experimental outcomes, with important implications for reproducibility and interpretation of functional drug screening. Collectively, this thesis establishes a multi-tumour PDTO research infrastructure and demonstrates its potential for biological discovery and therapeutic exploration. Importantly, it also highlights that organoids are experimentally shaped models rather than unbiased replicas of patient tumours. Their future will require improved establishment efficiency, standardized experimental conditions, appropriate model complexity and prospective clinical validation. Understanding both the capabilities and limitations of PDTOs is essential to ensure their reliable application in translational cancer research.

  • Open Access

    Comparative characterization of OncoPro™ and Wnt-Based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids

    by Sofie Seghers, Maxim Le Compte, Felicia Rodrigues Fortes, Jana Baroen, Jasper Ott, Geert Roeyen, Vera Hartman, Samir Kumar-Singh, Lenny Coppens, Michiel de Maat, et al.

    Background: Patient-derived tumor organoids (PDTOs) are strongly influenced by culture medium. We compared OncoPro™ (OP) Tumoroid Culture medium with conventional Wnt/R-spondin/noggin (Wnt) medium. This recently developed OP medium offers a standardized, serum-free alternative to Wnt-based formulations. Methods: We compared OP and Wnt media across 36 PDTO lines from various malignancies (colorectal, pancreatic, breast, lung, gastric, gastroesophageal junction, biliary head- and neck and uknown primary), assessing establishment success. Selected PDTO models were subjected to downstream characterization, including morphological assessment and bulk transcriptomic profiling with comparison to public single-cell RNA sequencing reference datasets (n=11), whole-exome sequencing (WES) (n=9), and pharmacological response profiling to a 33-drug panel (n=3). Results: Adaptation from Wnt medium to OP succeeded in 83.3% (15/18), whereas de novo establishment favored Wnt (33.3% vs 11.1%). Key oncogenic driver alterations were retained across matched organoid cultures, supporting preservation of tumor-relevant genomic features. Transcriptomic profiling confirmed preserved tumor-identity across media, while revealing different epithelial state programs: Wnt upregulated proliferation/stemness-associated genes (e.g. LGR5) and OP enriched adhesion-associated genes and inflammatory/TGF-β programs. In scRNA databases OP signatures preferentially mapped to malignant epithelial compartments in pancreatic cancer, whereas Wnt signatures were linked to non-malignant epithelium. Similarly, in colon cancer OP signature mapped predominantly to the malignant epithelial compartments. Drug (n=33) screening in pancreatic- and colorectal cancer PDTOs (n=3) demonstrated consistent medium-dependent shifts: Wnt-grown PDTOs were globally more sensitive in the screened subset, particularly to MAPK-axis inhibitors and apoptosis-sensitizers, while OP-grown PDTOs exhibited relative resistance. Conclusions: Culture medium composition is a key determinant of PDTO phenotype, transcriptome and drug sensitivity. Wnt medium was associated with drug-sensitive states, whereas OP medium was associated with adhesion- and inflammatory-related programs, relative resistance in the screened subset of 33 drugs and closer alignment with malignant epithelial programs in the analyzed pancreatic / colorectal cancer single-cell atlases.

  • Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022

    by Sofie Seghers, Pablo Mandó, Marc Eid, Charles J. Tan, Aarthi Jayraj, Karan Jatwani, Muhammad Salman Faisal, Vi Luong, Joanna A. Young, Laure-Anne Teuwen, et al.

    PURPOSE: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Value Framework (ASCO-VF) are tools designed to assess the value of anticancer therapies. International conferences are the primary venues for sharing trial outcomes, often influencing clinical practices even before full publications are available. This analysis compares the ESMO-MCBS and ASCO-VF in evaluating the benefit of all phase III trials presented at the 2022 ASCO Annual Meeting (AM) and to examine the level of agreement between these scales. METHODS: A systematic search of abstracts from the 2022 ASCO AM was conducted, focusing on phase III trial data presented. The clinical benefit of each abstract was assessed using both ESMO-MCBS and ASCO-VF, and Cohen's κ coefficients were calculated to analyze concordance between the tools. RESULTS: Out of 239 phase III trial abstracts, 90 trials involving 49,721 patients met the inclusion criteria. Of these, 36 (40%) could not be graded by ESMO-MCBS, mainly because of nonsignificant results. Among the 54 gradable abstracts, 61.1% (n = 33) were deemed to provide substantial clinical benefit. ASCO-VF was unable to grade 40 (44.4%) abstracts, with nonsignificant results being the leading cause. Of the 50 gradable abstracts, 20% (n = 10) were considered to offer substantial clinical benefit. Moderate agreement between ESMO-MCBS and ASCO-VF was observed (Cohen's kappa, 0.4783 [95% CI, 0.3673 to 0.6034]). No significant association was found between clinical benefit and research funding or the economic status of the trial's origin country. CONCLUSION: Both frameworks showed a high rate of nongradable studies, primarily because of nonsignificant results. ESMO-MCBS identified more studies with substantial clinical benefit, and the agreement between the two tools was moderate.

  • Open Access

    Challenges and prospects of LAG-3 inhibition in advanced gastric and gastroesophageal junction cancer: insights from the RELATIVITY-060 trial

    by Sofie Seghers, Andreas Domen, Hans Prenen

    Challenges and prospects of LAG-3 inhibition in advanced gastric and gastroesophageal junction cancer: insights from the RELATIVITY-060 trial


  • Open Access

    Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer

    by Denise van der Graaff, Sofie Seghers, Pieterjan Vanclooster, Christophe Deben, Timon Vandamme, Hans Prenen

    Colorectal cancer (CRC) remains a significant health burden globally, being the second leading cause of cancer-related mortality. Despite significant therapeutic advancements, resistance to systemic antineoplastic agents remains an important obstacle, highlighting the need for innovative screening tools to tailor patient-specific treatment. This review explores the application of patient-derived tumor organoids (PDTOs), three-dimensional, self-organizing models derived from patient tumor samples, as screening tools for drug resistance in CRC. PDTOs offer unique advantages over traditional models by recapitulating the tumor architecture, cellular heterogeneity, and genomic landscape and are a valuable ex vivo predictive drug screening tool. This review provides an overview of the current literature surrounding the use of PDTOs as an instrument for predicting therapy responses in CRC. We also explore more complex models, such as co-cultures with important stromal cells, such as cancer-associated fibroblasts, and organ-on-a-chip models. Furthermore, we discuss the use of PDTOs for drug repurposing, offering a new approach to identify the existing drugs effective against drug-resistant CRC. Additionally, we explore how PDTOs serve as models to gain insights into drug resistance mechanisms, using newer techniques, such as single-cell RNA sequencing and CRISPR-Cas9 genome editing. Through this review, we aim to highlight the potential of PDTOs in advancing our understanding of predicting therapy responses, drug resistance, and biomarker identification in CRC management.


  • A systematic review of patient-derived tumor organoids generation from malignant effusions

    by Sofie Seghers, Maxim Le Compte, Jeroen M.H. Hendriks, Paul Van Schil, Annelies Janssens, Reinier Wener, Niels Komen, Hans Prenen, Christophe Deben